MFOLFOX6 plus CEDIRANIB VS MFOLFOX6 plus BEVACIZUMAB IN PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED, DOUBLE-BLIND, PHASE II/III STUDY (HORIZON III)

被引：0
|
作者：
Schmoll, H. [1 ]
Cunningham, D. [2 ]
Sobrero, A. [3 ]
Karapetis, C. [4 ]
Rougier, P. [5 ]
Koski, S. L. [6 ]
Barker, P. [7 ]
Mookerjee, B. [7 ]
Robertson, J. [8 ]
van Cutsem, E. [9 ]
机构：
[1] Univ Halle Wittenberg, Dept Internal Med 4, Halle, Germany
[2] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[3] Osped San Martino Genova, Dept Med Oncol, Genoa, Italy
[4] Flinders Med Ctr, Adelaide, SA, Australia
[5] Hop Ambroise Pare, Boulogne Billancourt, France
[6] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[7] AstraZeneca, Wilmington, DE USA
[8] AstraZeneca, Macclesfield, Cheshire, England
[9] Univ Hosp Gasthuisberg, Dept Internal Med, B-3000 Louvain, Belgium
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：189 / 189
页数：1
相关论文
共 50 条
  • [21] Vandetanib plus mFOLFOX6 in patients with advanced colorectal cancer (CRC): A randomized, double-blind, placebo-controlled phase II study
    Yang, T. S.
    Oh, D. Y.
    Guimbaud, R.
    Szanto, J.
    Salek, T.
    Thurzo, L.
    Vieitez, J. M.
    Pover, G. M.
    Kim, T. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer, (vol 34, pg 1723, 2016)
    van Hazel
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (33) : 4059 - 4059
  • [23] Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
    Eiji Oki
    Yasunori Emi
    Takeharu Yamanaka
    Hiroyuki Uetake
    Kei Muro
    Takao Takahashi
    Takeshi Nagasaka
    Etsuro Hatano
    Hitoshi Ojima
    Dai Manaka
    Tetsuya Kusumoto
    Yu Katayose
    Toshiyoshi Fujiwara
    Kazuhiro Yoshida
    Michiaki Unno
    Ichinosuke Hyodo
    Naohiro Tomita
    Kenichi Sugihara
    Yoshihiko Maehara
    British Journal of Cancer, 2019, 121 : 222 - 229
  • [24] The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
    Bendell, Johanna C.
    Sauri, Tamara
    Cubillo Gracian, Antonio
    Alvarez, Rafael
    Lopez-Lopez, Carlos
    Garcia-Alfonso, Pilar
    Hussein, Maen
    Limon Miron, Maria-Luisa
    Cervantes, Andres
    Montagut, Clara
    Santos Vivas, Cristina
    Bessudo, Alberto
    Plezia, Patricia
    Moons, Veerle
    Andel, Johannes
    Bennouna, Jaafar
    van der Westhuizen, Andre
    Samuel, Leslie
    Rossomanno, Simona
    Boetsch, Christophe
    Lahr, Angelika
    Franjkovic, Izolda
    Heil, Florian
    Lechner, Katharina
    Krieter, Oliver
    Hurwitz, Herbert
    ONCOLOGIST, 2020, 25 (03): : E451 - E459
  • [25] Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial
    Heinrich, Kathrin
    Heinemann, Volker
    Westphalen, Benedikt
    Oecal, Osman
    Van Hazel, Guy A.
    Gibbs, Peter
    Seidensticker, Max
    Ricke, Jens
    Seidensticker, Ricarda
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)
    Oki, Eiji
    Emi, Yasunori
    Yamanaka, Takeharu
    Uetake, Hiroyuki
    Muro, Kei
    Takahashi, Takao
    Nagasaka, Takeshi
    Hatano, Etsuro
    Ojima, Hitoshi
    Manaka, Dai
    Kusumoto, Tetsuya
    Katayose, Yu
    Fujiwara, Toshiyoshi
    Yoshida, Kazuhiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Sugihara, Kenichi
    Maehara, Yoshihiko
    BRITISH JOURNAL OF CANCER, 2019, 121 (03) : 222 - 229
  • [27] CEDIRANIB plus FOLFOX/XELOX VERSUS PLACEBO plus FOLFOX/XELOX IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY (HORIZON II)
    Hoff, P. M.
    Hochhaus, A.
    Pestalozzi, B. C.
    Tebbutt, N. C.
    Li, J.
    Kim, T. W.
    Pike, L.
    Fielding, A.
    Robertson, J.
    Saunders, M. P.
    ANNALS OF ONCOLOGY, 2010, 21 : 9 - 9
  • [28] A PHASE II STUDY OF CEDIRANIB IN COMBINATION WITH MFOLFOX6 IN JAPANESE PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (CRC)
    Muro, K.
    Kato, T.
    Yamaguchi, K.
    Bando, H.
    Hazama, S.
    Amagi, K.
    Baba, H.
    Denda, T.
    Sakamoto, J.
    Mishima, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 199 - 199
  • [29] PHASE II TRIAL OF mFOLFOX6/CapeOX PLUS BEVACIZUMAB WITH OXALIPLATIN IN A STOP AND GO FASHION IN ADVANCED mCRC
    Gamoh, M.
    Shimodaira, H.
    Murakawa, Y.
    Kato, S.
    Amagai, K.
    Isoge, H.
    Niitani, T.
    Itoh, J.
    Yoshioka, T.
    Ishioka, C.
    ANNALS OF ONCOLOGY, 2013, 24
  • [30] SAPPHIRE: A Randomized Phase II Study of mFOLFOX6
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 19 - 20
12345